Publications

ENG

Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.

Abstract

BACKGROUND: Residual systemic inflammation, which is associated with non-AIDS clinical outcomes, may persist despite viral suppression.

Authors: Musinguzi N Castillo-Mancilla J Morrow M Byakwaga H Mawhinney S Burdo TH Boum Y Muzoora C Bwana BM Siedner MJ Martin JN Hunt PW Bangsberg DR Haberer JE
Journal Reference: Journal of acquired immune deficiency syndromes (1999) 2019 Dec 01; 82(4); 386-391. doi: 10.1097/QAI.0000000000002148. Epub 2019 11 01
ENG

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.

Abstract

BACKGROUND: Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial.

Authors: Mulangu S Dodd LE Davey RT Tshiani Mbaya O Proschan M Mukadi D Lusakibanza Manzo M Nzolo D Tshomba Oloma A Ibanda A Ali R Coulibaly S Levine AC Grais R Diaz J Lane HC Muyembe-Tamfum JJ Sivahera B Camara M Kojan R Walker R Dighero-Kemp B Cao H Mukumbayi P Mbala-Kingebeni P Ahuka S Albert S Bonnett T Crozier I Duvenhage M Proffitt C Teitelbaum M Moench T Aboulhab J Barrett K Cahill K Cone K Eckes R Hensley L Herpin B Higgs E Ledgerwood J Pierson J Smolskis M Sow Y Tierney J Sivapalasingam S Holman W Gettinger N Vallée D Nordwall J
Journal Reference: The New England journal of medicine 2019 Nov 27; (); Array. doi: 10.1056/NEJMoa1910993. Epub 2019 11 27
ENG

Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda

Abstract

INTRODUCTION: Yellow fever is endemic in specific regions of sub-Saharan Africa and the Americas, with recent epidemics occurring on both continents.

Authors: Derick Kimathi Aitana Juan Philip Bejon Rebecca F. Grais George M. Warimwe
Journal Reference: Wellcome Open Research 2019 Nov 21; 4:182;10.12688/wellcomeopenres.15579.1
Yellow Fever Vaccination
ENG

Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea.

Abstract

BACKGROUND: As part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP.

Authors: Juan-Giner A Tchaton M Jemmy JP Soumah A Boum Y Faga EM Cisse M Grais RF
Journal Reference: Vaccine 2018 Sep 25; (); Array. doi: 10.1016/j.vaccine.2018.09.009. Epub 2018 09 25
Ebola virus disease Guinea Health-care workers Safety Surveillance rVSV vaccine
ENG

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.

Abstract

Delamanid should be effective against highly resistant strains of M. tuberculosis, but uptake has been slow globally.

Authors: Seung KJ Khan P Franke MF Ahmed S Aiylchiev S Alam M Putri FA Bastard M Docteur W Gottlieb G Hewison C Islam S Khachatryan N Kotrikadze T Khan U Kumsa A Lecca L Tassew YM Melikyan N Naing YY Oyewusi L Rich M Wanjala S Yedilbayev A Huerga H Mitnick CD
Journal Reference: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Nov 02; (); Array. doi: 10.1093/cid/ciz1084. Epub 2019 11 02
antitubercular agents delamanid extensively drug-resistant tuberculosis multidrug-resistant tuberculosis
ENG

Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi).

Abstract

: Despite substantial progress in antiretroviral therapy (ART) scale up, some people living with HIV (PLHIV) continue to present with advanced HIV disease, contributing to ongoing HIV-related morbidity and mortality.: We aimed to quantify population-le

Authors: Chihana ML Huerga H Van Cutsem G Ellman T Goemaere E Wanjala S Masiku C Szumilin E Etard JF Maman D Davies MA
Journal Reference: Global health action 2019 ; 12(1); 1679472. doi: 10.1080/16549716.2019.1679472. Epub 2019 11 04
ART Africa CD4 HIV population-level
ENG

Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in African children.

Abstract

Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC.

Authors: Ding J Coldiron ME Assao B Guindo O Blessborn D Winterberg M Grais RF Koscalova A Langendorf C Tarning J
Journal Reference: Clinical pharmacology and therapeutics 2019 Oct 25; (); Array. doi: 10.1002/cpt.1707. Epub 2019 10 25
ENG

Should urine-LAM tests be used in TB symptomatic HIV-positive patients when no CD4 count is available? A prospective observational cohort study from Malawi.

Abstract

BACKGROUND: Current eligibility criteria for urine lateral-flow-lipoarabinomannan assay (LF-LAM) in ambulatory, HIV-positive patients rely on the CD4 count.

Authors: Huerga H Mathabire Rucker SC Bastard M Dimba A Kamba C Amoros I Szumilin E
Journal Reference: Journal of acquired immune deficiency syndromes (1999) 2019 Oct 16; (); Array. doi: 10.1097/QAI.0000000000002206. Epub 2019 10 16
ENG

Evaluation of OMNIgene® SPUTUM and ethanol reagent for preservation of sputum prior to Xpert and culture testing in Uganda.

Abstract

Xpert MTB/RIF (Xpert) and culture are the most reliable methods for tuberculosis diagnosis but are still poorly accessible in many low resource countries.

Authors: Ardizzoni E Orikiriza P Ssuuna C Nyehangane D Gumsboga M Taremwa IM Turyashemererwa E Mwanga-Amumpaire J Langendorf C Bonnet M
Journal Reference: Journal of clinical microbiology 2019 Oct 16; (); Array. doi: 10.1128/JCM.00810-19. Epub 2019 10 16
ENG

Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea.

Abstract

BACKGROUND: Alongside the clinical aspects of the immunogenicity and safety trial of an Ebola vaccine deployed among front-line workers, a qualitative study was conducted to describe motivations behind individuals' decisions to partici

Authors: Grantz KH Claudot P Kambala M Kouyaté M Soumah A Boum Y Juan-Giner A Jemmy JP Cummings DAT Grais RF
Journal Reference: Vaccine 2019 Oct 14; (); Array. doi: 10.1016/j.vaccine.2019.09.094. Epub 2019 10 14
Ebola virus disease Guinea Healthcare workers Qualitative Research design rVSV vaccine